Amgen Reveals Ocrelizumab Biosimilar Ambitions

CEO Highlights Ocrevus Challenger And Discusses Denosumab Rivals

 
• By Dave Wallace
  
Amgen discussed its biosimilars business at JPM (Shutterstock)

More from Biosimilars

More from Business